News 2024.02.09 Announcement iXgene Inc. signs License Agreement with Keio University Educational Corporation for Commercialization of Suicide Gene Transfer iPS Cell Patents 2023.10.10 Press Release Announcement of a three-way joint research agreement between iXgene, Keio University School of Medicine, and Sumitomo Pharma for the practical application of a treatment for malignant brain tumors using genome-edited iPS cells. 2023.01.05 Press Release Keio Innovation Initiative/University of Tokyo Collaborative Creation Platform Development/MSF Capital Partners/Green Core to carry out third-party allotment capital increase totaling 600 million yen